Drug Trial Radar · NCT06319027
Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Apr 11, 2024
Primary completion
May 31, 2027
Study completion May 31, 2027
Sponsor
- Lead sponsor
- ECOG-ACRIN Cancer Research GroupResearch network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Mar 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial studies whether different imaging techniques can provide additional and more accurate information than the usual approach for assessing the activity of tumors in patients with newly diagnosed glioblastoma. The usual approach for this currently is magnetic resonance imaging (MRI). This study is trying to learn more about the meaning of changes in MRI scans after treatment, as while the appearance of some of these changes may reflect progressing tumor, some may be due the treatment. Dynamic susceptibility contrast (DSC)-MRIs, along with positron emission tomography (PET) and/or magnetic resonance (MR) spectroscopy, may help doctors tell which changes are a reflection of the treatment and which changes may be due to progressing tumor.
Conditions
- Glioblastoma, IDH-Wildtype
Interventions
Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance ImagingProcedure
Undergo DSC-MRI
Fluciclovine F18Other
Given IV
Gadolinium-ChelateDrug
Receive gadolinium-based contrast agent
Magnetic Resonance SpectroscopyProcedure
Undergo MR spectroscopy
Positron Emission TomographyProcedure
Undergo PET scan
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survival (OS)Time frame: From biomarker collection to death due to any cause, assessed up to 6 years
- Event free survival (EFS)Time frame: From biomarker collection until progression by Neurological Assessment in Neuro-Oncology (NANO) criteria or death, assessed up to 6 years
Locations
18 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama · Recruiting
Cedars-Sinai Medical Center
Los Angeles, California · Recruiting
Baptist MD Anderson Cancer Center
Jacksonville, Florida · Recruiting
Moffitt Cancer Center
Tampa, Florida · Recruiting
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia · Recruiting
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan · Recruiting
Carolinas Medical Center/Levine Cancer Institute
Charlotte, North Carolina · Suspended
Duke University Medical Center
Durham, North Carolina · Recruiting
Wake Forest University Health Sciences
Winston-Salem, North Carolina · Recruiting
Rhode Island Hospital
Providence, Rhode Island · Suspended
Edwards Comprehensive Cancer Center
Huntington, West Virginia · Recruiting
West Virginia University Healthcare
Morgantown, West Virginia · Recruiting
University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
Madison, Wisconsin · Recruiting
University of Wisconsin Carbone Cancer Center - University Hospital
Madison, Wisconsin · Recruiting
Froedtert Menomonee Falls Hospital
Menomonee Falls, Wisconsin · Recruiting
Medical College of Wisconsin
Milwaukee, Wisconsin · Recruiting
Drexel Town Square Health Center
Oak Creek, Wisconsin · Recruiting
Froedtert West Bend Hospital/Kraemer Cancer Center
West Bend, Wisconsin · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.